Trial · NCT02138253
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score | 24 months | The Full Analysis Set (FAS) consisted of all randomized subjects who received at least 1 dose of study drug. | participants | NUMBER |
| SECONDARY | Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score (Observed Cases Only) | 24 months | Full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Number of Participants With At Least a One Stage Reduction From Baseline in Ishak Fibrosis Score | 12 months | Full analysis set, the # of subject analyzed included subjects with an observed Ishak Fibrosis Score at 12 months. | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Alanine Aminotransferase (ALT) - Change From Baseline | Baseline and 24 months | Full analysis set, the # of subject analyzed included subjects with an observed ALT at 24 months. | U/L | MEAN |
| SECONDARY | Aspartate Aminotransferase (AST) Change From Baseline | Baseline and 24 months | Full analysis set, the # of subject analyzed included subjects with an observed AST at 24 months. | U/L | MEAN |
| SECONDARY | Caspase 3/7 Change From Baseline | Baseline and 24 months | Full analysis set, the # of subject analyzed included subjects with an observed Caspase 3/7 at 24 months. | Raw RLU | MEAN |
| SECONDARY | cCK18/M30 Change From Baseline | Baseline and 24 months | Full analysis set, the # of subject analyzed included subjects with an observed cCK18/M30 at 24 months. | U/L | MEAN |
| SECONDARY | flCK18/M65 Change From Baseline | Baseline and 24 months | Full analysis set, the # of subject analyzed included subjects with an observed flCK18/M65 at 24 months. | U/L | MEAN |
| SECONDARY | Ishak Modification of Knodell Histological Activity Index - Interface Hepatitis | 24 months | Full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Ishak Modification of Knodell Histological Index - Confluent Necrosis | 24 months | Full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Ishak Modification of Knodell Histological Index - Parenchymal Injury | 24 months | Full analysis set | Participants | COUNT_OF_PARTICIPANTS |
| SECONDARY | Ishak Modification of Knodell Histological Index - Portal Inflammation | 24 months | Full analysis set | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02138253/outcomes